Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

June 20, 2024 updated by: Cara Therapeutics, Inc.

A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica

This is a 2-part, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin for moderate-to-severe pruritus in adult subjects with NP.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Part A of this study will evaluate the benefit-risk of 3 doses of difelikefalin compared to placebo. The dose with the best benefit-risk profile will be further evaluated in Part B. Part A of this study comprises a 28-day Screening Period, a 7-day Run-in Period, an 8-week Double-blind Treatment Period, a 2-week Treatment Discontinuation Period, and a Safety Follow-up Visit (14 days after the last dose of study treatment).

Part B of this study will evaluate the efficacy, safety, and tolerability of oral difelikefalin. The dose of oral difelikefalin to be assessed in Part B will depend on the results of Part A. Part B of this study comprises a 28-day Screening Period, a 7-day Run-in Period, an 8-week Double-blind Treatment Period, up to a 52-week OLE Period, and a Safety Follow-up Visit.

Subjects who participated in Part A of the study may not participate in Part B.

All subjects will sign an informed consent form (ICF) and undergo screening for study eligibility.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
214

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Canada
      • Montréal, Canada
        • Cara Therapeutics Study Site
      • Oshawa, Canada
        • Cara Therapeutics Study Site
      • Québec, Canada
        • Cara Therapeutics Study Site
    • Ontario
      • Oakville, Ontario, Canada
        • Cara Therapeutics Study Site
      • Peterborough, Ontario, Canada
        • Cara Therapeutics Study Site
      • Richmond Hill, Ontario, Canada
        • Cara Therapeutics Study Site
      • Toronto, Ontario, Canada
        • Cara Therapeutics Study Site
    • Quebec
      • Sherbrooke, Quebec, Canada
        • Cara Therapeutics Study Site
  • Germany
      • Bad Bentheim, Germany
        • Cara Therapeutics Study Site
      • Berlin, Germany
        • Cara Therapeutics Study Site
      • Heidelberg, Germany
        • Cara Therapeutics Study Site
      • Langenau, Germany
        • Cara Therapeutics Study Site 2
      • Langenau, Germany
        • Cara Therapeutics Study Site
  • Poland
      • Katowice, Poland
        • Cara Therapeutics Study Site
      • Katowice, Poland
        • Cara Therapeutics Study Site 2
      • Sosnowiec, Poland
        • Cara Therapeutics Study Site
      • Szczecin, Poland
        • Cara Therapeutics Study Site
      • Wrocław, Poland
        • Cara Therapeutics Study Site
  • Spain
      • Bilbao, Spain
        • Cara Therapeutics Study Site
      • Madrid, Spain
        • Cara Therapeutics Study Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35244
        • Cara Therapeutics Study Site
    • Arizona
      • Phoenix, Arizona, United States, 85032
        • Cara Therapeutics Study Site
    • Arkansas
      • Fayetteville, Arkansas, United States, 72703
        • Cara Therapeutics Study Site
      • Hot Springs, Arkansas, United States, 71913
        • Cara Therapeutics Study Site
    • California
      • Encino, California, United States, 91436
        • Cara Therapeutics Study Site
      • Fountain Valley, California, United States, 92708
        • Cara Therapeutics Study Site
      • Los Angeles, California, United States, 90045
        • Cara Therapeutics Study Site
      • Northridge, California, United States, 91324
        • Cara Therapeutics Study Site
      • Valencia, California, United States, 91355
        • Cara Therapeutics Study Site
    • Florida
      • Coral Gables, Florida, United States, 33134
        • Cara Therapeutics Study Site
      • Hollywood, Florida, United States, 33021
        • Cara Therapeutics Study Site
      • Lutz, Florida, United States, 33558
        • Cara Therapeutics Study Site
      • Margate, Florida, United States, 33063
        • Cara Therapeutics Study Site
      • Tampa, Florida, United States, 33607
        • Cara Therapeutics Study Site
    • Indiana
      • Indianapolis, Indiana, United States, 46250
        • Cara Therapeutics Study Site
      • Plainfield, Indiana, United States, 46168
        • Cara Therapeutics Study Site
      • West Lafayette, Indiana, United States, 47906
        • Cara Therapeutics Study Site
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70809
        • Cara Therapeutics Study Site
      • Baton Rouge, Louisiana, United States, 70808
        • Cara Therapeutics Study Site
      • Metairie, Louisiana, United States, 70006
        • Cara Therapeutics Study Site
      • New Orleans, Louisiana, United States, 70115
        • Cara Therapeutics Study Site
    • Maryland
      • Rockville, Maryland, United States, 20850
        • Cara Therapeutics Study Site
    • Michigan
      • Fort Gratiot, Michigan, United States, 48059
        • Cara Therapeutics Study Site
    • Nevada
      • Reno, Nevada, United States, 89509
        • Cara Therapeutics Study Site
    • New Hampshire
      • Portsmouth, New Hampshire, United States, 03801
        • Cara Therapeutics Study Site
    • New Jersey
      • Verona, New Jersey, United States, 07044
        • Cara Therapeutics Study Site
    • North Dakota
      • Fargo, North Dakota, United States, 58103
        • Cara Therapeutics Study Site
    • Ohio
      • Boardman, Ohio, United States, 44512
        • Cara Therapeutics Study Site
      • Mason, Ohio, United States, 45040
        • Cara Therapeutics Study Site
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • Cara Therapeutics Study Site
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Cara Therapeutics Study Site
    • Tennessee
      • Thompson's Station, Tennessee, United States, 37179
        • Cara Therapeutics Study Site
    • Texas
      • Dallas, Texas, United States, 75230
        • Cara Therapeutics Study Site
      • Houston, Texas, United States, 77056
        • Cara Therapeutics Study Site
      • Pflugerville, Texas, United States, 78660
        • Cara Therapeutics Study Site
      • San Antonio, Texas, United States, 78213
        • Cara Therapeutics Study Site
      • Webster, Texas, United States, 77598
        • Cara Therapeutics Study Site
    • Washington
      • Spokane, Washington, United States, 99202
        • Cara Therapeutics Study Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

To be eligible for inclusion into the study, a patient must meet the following criteria:

  • Subject has clinically confirmed diagnosis of active Notalgia Paresthetica;
  • Subject has a history of chronic pruritus due to Notalgia Paresthetica;
  • Subject has moderate to severe pruritus;
  • Female subject is not pregnant or nursing during any period of the study.

Key Exclusion Criteria:

A patient will be excluded from the study if any of the following criteria are met:

  • Subject has pruritus attributed to a cause other than Notalgia Paresthetica;
  • Subject has any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Difelikefalin 2.0 mg tablets
Oral difelikefalin 2.0 mg tablet administered twice daily
Drug: difelikefalin 2.0 mg tablets
Oral difelikefalin 2.0 mg administered twice daily
Other Names:
  • CR845
Active Comparator: Difelikefalin 1.0 mg tablets
Oral difelikefalin 1.0 mg tablet administered twice daily
Drug: difelikefalin 1.0 mg tablets
Oral difelikefalin 1.0 mg administered twice daily
Other Names:
  • CR845
Active Comparator: Difelikefalin 0.25 mg tablets
Oral difelikefalin 0.25 mg tablet administered twice daily
Drug: difelikefalin 0.25 mg tablets
Oral difelikefalin 0.25 mg administered twice daily
Other Names:
  • CR845
Placebo Comparator: Placebo tablets
Oral placebo tablet administered twice daily
Drug: Placebo tablets
Oral Placebo administered twice daily

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Proportion of subjects achieving ≥4-point improvement from baseline in the weekly mean of the daily 24-hour I-NRS score
Time Frame: Baseline, Week 8
Baseline, Week 8

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Proportion of subjects achieving ≥4-point improvement from baseline in the weekly mean of the daily 24-hour I-NRS score at Week 4 in Part B
Time Frame: Baseline, Week 4
Baseline, Week 4
Proportion of subjects achieving ≥4-point improvement from baseline in the weekly mean of the daily 24-hour I-NRS score at Week 2 in Part B
Time Frame: Baseline, Week 2
Baseline, Week 2
Proportion of subjects achieving ≥4-point improvement from baseline in the weekly mean of the daily 24-hour I-NRS score at Week 1 in Part B
Time Frame: Baseline, Week 1
Baseline, Week 1
Change from Baseline in the Numeric Rating Scale of Burning Sensation and Skin Tingling at Week 8 in Part B
Time Frame: Baseline, Week 8
Baseline, Week 8
Proportion of Subjects with H-IGA of Clear or Almost Clear at Week 8 in Part B
Time Frame: Week 8
Week 8
Proportion of ≥4-point Improvement in Daily I-NRS at Day 2 in Part B
Time Frame: Day 2
Day 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cara Therapeutics, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Cara Therapeutics, Cara Therapeutics

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 1, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 22, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 7, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 25, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 3, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 7, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 21, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 20, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CR845-310601

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings